Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in relapsed/refractory CNS lymphoma
NCT05485753Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emfizatamab in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 17 days, Maximum Tolerated Dose at 17 days and 3 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
emfizatamab
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT05485753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485753.